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Abstract
Background: the constantly growing amount of dif-
ferent kinds of colloid fluids necessitates comparative
investigations with regards to the safety and effectivity
in clinical use of these preparations.  Hence we com-
pared  three  colloid  fluids  in  an  observational  study.
the objective was the exploration of the influence of
these  three  colloids  on  blood  coagulation,  hemody-
namics and renal function of the cardiac surgical pa-
tient. 
Methods: we included 90 patients undergoing an elec-
tive open-heart surgery with the use of the heart-lung
machine and observed them consecutively.   Group 1
[gelatin 4% (n = 30)], Group 2 [HEs 200/0,5 (n =
30)] and Group 3 [HEs 130/0,42 (n = 30)]. we mea-
sured the perioperative volume replacement, the ad-
ministration of blood- and coagulation-products, the
application  of  catecholamines,  the  renal  function,
blood gas and the platelet aggregation using multiplate
electrode  analyzer  (Multiplateﾮ,  dynabyte  medical,
Munich, Germany). 
Results: the gelatin-group needed significantly more
norepinephrine  than  the  HEs  130/0.42  group.  the
responsible surgeon considered the blood coagulation
in  the  HEs  200/0.5  group  most  frequently  as  im-
paired. furthermore we saw a significant decrease in
platelet function in the HEs 200/0.5 group when per-
forming  the  multiplateﾮ-analysis  (adP-and  col-
test). HEs 130/0.4 as well as gelatin 4% showed no
significant  change  in  platelet  function.  the  gelatin-
group and the HEs 200/0.5 needed significantly more
aprotinine than the HEs 130/0.4 group. we saw no
significant  difference  with  regards  to  administration
of blood and coagulation products between the three
groups. the urinary excretion during the intervention
was  significantly  higher  in  the  HEs  200/0.5  group
and  in  the  gelatin  group  than  in  the  HEs  130/0.4
group. 
Conclusions: our results confirm the lower stabilizing
effect of gelatin on circulation during fluid resuscita-
tion. the blood coagulation was mostly impaired due
to HEs 200/0.5 confirmed by the multiplateﾮ-analysis
as well as by different clinical findings. 
IntRoductIon
cardiac surgery is associated with extended blood loss
resulting in hypovolemia, circulatory dysregulation and
deficient  tissue  perfusion.  therefore  an  urgent  ade-
quate intravascular volume therapy is essential for the
management of these patients and in avoiding organ
dysfunction. the advantage of colloids over crystal-
loids in effective volume replacement and improving
haemodynamics has been confirmed and reviewed in
several studies [1-3]. Hence colloids are widely used in
fluid  resuscitation  and  especially  hydroxyethylstarch
(HEs) has become an established approach to correct
hypovolemia under a variety of conditions [4]. 
the  origin  of  hydroxyethylstarch  is  waxy  maize
amylopectin, a highly branched polysaccharide similar
to glycogen. the structure of HEs is determined by
mainly 1-4 linkages of polymerized glucose and 1-6
branching linkages. thus the degradation of HEs by
the serum _-amylase is elongated and its elimination
from the blood circulation delayed. It was shown that
the molecular weight (Mw) plays only a minor role in
determining the pharmacological profile of HEs solu-
tions [5]. Rather the degree of molar substitution (Ms)
and the substitution ratio at c2/c6 seem to determine
the pharmacological profile of each HEs preparation
[6].
diverse  HEs-preparations  are  considered  to  alter
blood coagulation and inducing platelet dysfunction to
a certain extend. However, HEs preparations repre-
sent a good compromise of sufficiently treating hypo-
volemia and an overall low rate of adverse drug reac-
tions [7]. there is a wide range of HEs preparations
available and the last 3rd generation of HEs has been
approved  by  the  food  and  drug  administration
(fda) in 2008 [8]. the 3rd generation of HEs prepa-
rations has a Mw of 130 kd and a Ms <0,.supposed
to alter coagulation to a lower extend than HEs prepa-
rations with a higher Mw (200 kd) and a higher Ms
(0.5) [8, 9]. However some authors saw no differences
with regard to coagulation, bleeding and transfusion
requirements when comparing different HEs prepara-
tions [10, 11]. 
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three  colloids  (6%  HEs  130/0.42,  4%  gelatin,  6%
HEs 200/0,5) in respective to coagulation, estimated
blood  loss,  transfusion  requirements,  hemodynamics
and renal function.  besides collecting and evaluating
clinical data we used the multiple electrode analyzer
(Multiplateﾮ) for detecting platelet dysfunctions.
MEtHods
after the approval of the local ethics committee, we
separated  a  collective  of  90  patients  in  three  equal
groups each counting 30 patients. we included only
patients who had to undergo an elective open-heart
surgery with the use of the heart-lung machine in our
observations. further inclusion criteria were the mini-
mum age of 18 years and no contraindications against
the administration of colloids. the observation period
started  with  the  anesthetic  induction  and  ended  24
hours  after  the  open-heart  surgery  on  the  Icu.  we
collected diverse clinical data during this period and it
was documented in a standardized sheet.
the first group received 6% HEs 130/0,42 (veno-
fundinﾮ,  b.  braun),  the  second  group  4%  gelatin
(Gelafundinﾮ, b. braun) and the third group received
6% HEs 200/0,5 (Hemohesﾮ, b. braun). because we
performed an observational study during clinical rou-
tine without a study setting there was no randomiza-
tion and blinding of the 90 patients possible. In the
range of our clinical routine we administered each pa-
tient 500 ml of the respective colloid during the anes-
thetic induction. If necessary the respective patient re-
ceived only the same colloid during the whole open-
heart surgery. 
Preoperatively we documented the age, sex, body-
weight, height, the body mass index (bMI), the con-
comitant  medication  and  concomitant  diseases  of
each  patient.  we  registered  anamnestic  coagulation
disorders, the bleeding tendency in family history and
classified  each  patient  according  to  the  asa-score.
furthermore  we  calculated  the  Euroscore  (http://
euroscore.org/calc.html.) for each patient, which de-
scribes  the  probability  of  mortality  during  cardiac
surgery. also the main diagnosis, the type of surgery
being performed and different time intervals concern-
ing the surgery and the hospitalization were captured. 
we  separated  the  observation  period  in  phase  1
(from the beginning of the anesthetic induction till the
end  of  surgery)  and  in  phase  2  (from  the  end  of
surgery till 24 hours stay on the Icu). Perioperatively
we documented the amount of crystalloids adminis-
trated, the administration of blood components (red
blood cells, fresh frozen plasma, platelet concentrates)
and the urinary excretion. besides we registered the
use and given amount of aprotinine, heparine, prota-
mine  and  catecholamine’s  (norepinephrine,  dobuta-
mine). all data concerning the monitoring of the car-
diovascular system as well as diverse laboratory para-
meters and blood gas values measured routinely dur-
ing open-heart surgery were captured for each patient.
In  addition  the  responsible  surgeon  evaluated  and
graded the blood coagulation during the surgery. 
for assessing platelet function we used the multi-
plate electrode analyzer (Multiplateﾮ, dynabyte med-
ical,  Munich,  Germany).  the  blood  for  the  multi  -
plateﾮ analysis  was  drawn  from  each  patient  before
and after the administration of the respective colloid
during the anesthetic induction. the infused amount
of each colloid was exactly 500 ml. the analysis was
performed immediately in a near-patient setting. the
multiplate  electrode  analyzer  measures  electrical  im-
pedance between electrodes immersed in whole blood.
blood is stirred using an electromagnetic stirrer by 800
rpm.  the  attachment  of  platelet  aggregates  on  the
electrodes increase the impedance between them. the
impedance change is transformed to arbitrary aggrega-
tion  units  (au)  by  the  system  software  and  plotted
against time [12]. the multiplateﾮ system allows the
evaluation of platelet function after being activated by
the agonists’ adenosine diphosphate (adP, 6.4 ﾵM),
collagen (col, 3.2 ﾵg/ml) and thrombin-receptor-ac-
tivated  protein  (tRaP,  32  ﾵM).  the  three  agonists
used were added to 600 ﾵl pre-warmed, diluted blood
into  single-use  test  cells.  these  test  cells  contain  4
metal electrodes which are paired as two independent
sensor units. 
for statistical analysis the standard program sas
(Release 9.1) was used. the chi-square-test was used
for the comparison of the three treatments in case of
discontinuous variables. If sas gave a warning that
cells  have  expected  counts  less  than  5  the  test
switched to the likelihood ratio test. the continuous
parameters  were  compared  with  the  overall  f-test 
of the GlM-procedure fol-lowed with the lsd-test
as post-hoc-test. the test level is assumed with a =
0.05.
REsults
our results reveal a significant difference between the
three groups concerning the bodyweight, the height,
the bMI and the Euroscore (table 1). the 4% gelatin
group was significantly taller and had a significantly
higher body weight than the 6% HEs130/0.42 group.
the Euroscore of the 6% HEs 130/0.42 group was
significantly higher than the 6% HEs 200/0.5 group.
for all other preoperative parameters there was no sig-
nificant difference between the three groups (table 1
and 2). 
during surgery (phase 1) the 4% gelatin group and
the  6%  HEs  200/0.5  group  received  significantly
more  aprotinine  than  the  6%  HEs  130/0.42  group.
the urinary excretion during phase 1 was significantly
lower in the 6% HEs 130/0.42 group (table 3). we
saw no significant difference with regards to the ad-
ministration  of  blood  and  coagulation  products  be-
tween the three groups. 
on Icu (phase 2) the 4% gelatin group received
significantly more norepinephrine than the two other
groups (table 4). we saw no significant difference be-
tween the three groups with regards to the administra-
tion of other catecholamine’s. 
furthermore  we  saw  a  significant  decrease  in
platelet function in the 6% HEs 200/0.5 group when
performing  the  multiplateﾮ analysis  (adP-and 
col-test, fig. 5 and 6). there was no significant de-
crease  in  the  tRaP-test  (fig.  3).  the  6%  HEs
130/0.42  group  as  well  as  well  as  the  4%  gelatin
EuRoPEan JouRnal of MEdIcal REsEaRcH 384 september 24, 2010
3) Winterhalter_Umbruchvorlage  10.09.10  18:54  Seite 384EuRoPEan JouRnal of MEdIcal REsEaRcH september 24, 2010 385
Table 1. demographic data, intraoperative and postoperative variables.
variables 6% HES 130/0.42 4% gelatin 6% HES 200/0.5 p-value
(n=30) (n=30) (n=30)
female (n) 12 5 12 0.0827
age in years ﾱsd 69 ﾱ 13 66 ﾱ 12 67 ﾱ 10 > 0.2
body weight in kg  ﾱsd 72 ﾱ 15 84 ﾱ 18 75 ﾱ 12 < 0.05
body height in cm  ﾱsd 167 ﾱ 9 173 ﾱ 8 168 ﾱ 10 < 0.05
body mass index in kg/m_  ﾱsd 26 ﾱ4 28 ﾱ 6 26 ﾱ 4 < 0.05
ejection fraktion in %  ﾱsd 59 ﾱ 15 54 ﾱ 18 63 ﾱ 15 > 0.2
euroscore (%)  ﾱsd 6 ﾱ 3 4 ﾱ 2 4 ﾱ 3 < 0.05
asa score (asa 3), n 25 23 24 > 0.2
anamnestic coagulation disorder 10 0 > 0.2
aortocoronary bypass
artery graft > 0.2
one artery graft 13 19 17 > 0.2
two artery grafts 02 2 > 0.2
three artery grafts 22 1 > 0.2
venous graft 0.1835
one venous graft 41 3 > 0.2
two venous grafts 3 11 10 > 0.2
three venous grafts 87 4 > 0.2
four venous grafts 00 1 > 0.2
valve replacement
mitral valve replacement 31 0 0.1014
aortic valve replacement 10 6 10 > 0.2
valve reconstruction
mitral valve reconstruction 12 1 > 0.2
aortic valve reconstruction 10 0 > 0.2
temperature during cPb (30-35ﾰc) 25 26 27 > 0.2
cardiopegia ( st. thomas) 23 27 28 0.0557
duration of surgery  (min ﾱsd) 198 ﾱ 59 199 ﾱ 33 178 ﾱ 36 0.1214
duration of cPb in (min ﾱsd) 104 ﾱ 37 93 ﾱ 27 89 ﾱ 32 0.196
aortic cross-clamp time (min ﾱsd) 59 ﾱ 24 48 ﾱ 18 49 ﾱ 22 0.1229
Icu-stay in days ﾱsd 1 ﾱ 1 2 ﾱ 5 1 ﾱ 1 > 0.2
hospitalization in days ﾱsd 12 ﾱ 6 11 ﾱ 6 10 ﾱ 5 > 0.2
Fig. 1. Multiplateﾮ analysis: adP-test.
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tion. these data are supported by the evaluation of
the  responsible  surgeon  who  considered  the  blood
coagulation in the 6% HEs 200/0.5 group most fre-
quently impaired.
dIscussIon
Hyovolemia is widespread among patients in cardiac
surgery and an adequate fluid resuscitation is essential
for the outcome of these patients. a change in demo-
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Table 2. concomitant medication and concomitant diseases.
variable 6% HES 130/0.42 4% gelatin 6% HES 200/0.5 p-value
(n=30) (n=30) (n=30)
asperine 15 17 19 > 0.2
nsaR 03 1 0.1129
clopidogrel 15 5 0.1351
phenprocoumon 21 3 > 0.2
beta blocker 19 19 19 > 0.2
calcium channel blocker 63 3 > 0.2
acE-inhibitors 17 17 17 > 0.2
diuretic 14 16 13 > 0.2
digoxin 34 2 > 0.2
statine drug 14 17 17 > 0.2
nitrate 85 7 > 0.2
arterial hypertension 21 18 20 > 0.2
pulmonary hypertension 33 1 > 0.2
diabetes mellitus 48 8 > 0.2
smoker 4 10 10 0.1176
hypercholesteremia 11 11 15 > 0.2
adiposity 7 12 10 > 0.2
coronary artery disease 20 21 26 0.1636
familial heart diseases 13 6 0.1166
left main (coronary artery) stenosis 69 11 > 0.2
multi-vessel coronary disease 16 20 19 > 0.2
myocardial infarction 27 8 0.1192
atrial fibrillation 44 3 > 0.2
ischemic cardiomyopathy 22 0 0.1886
mitral valve insufficiency 97 6 > 0.2
aortic valve insufficiency 84 4 > 0.2
aortic valve stenosis 10 4 10 0.1293
coPd 7 10 4 0.1869
Table 3. crystalloids, blood components, urinary excretion, coagulation products and catecholamine from the anesthetic induc-
tion till the end of surgery (phase 1).
variable 6% HES 130/0.42 4% gelatin 6% HES 200/0.5 p-value
(n=30) (n=30) (n=30)
saline (ml) ﾱsd 2008 ﾱ 476 2028 ﾱ 799 2007 ﾱ 357 > 0.2
other crystalloides (ml) ﾱsd 1318 ﾱ 265 1289 ﾱ 326 1231 ﾱ 423 > 0.2
red cell concentrate (n)  ﾱsd 3 ﾱ 1 3 ﾱ 2 3 ﾱ 1 > 0.2
fresh frozen plasma (n) ﾱsd 4 ﾱ 1 3 ﾱ 1 3 ﾱ 1 > 0.2
platelet concentrate (n) ﾱsd 2 ﾱ 1 2 ﾱ 1 2 ﾱ 0.0 > 0.2
bicarbonate 8.4% (ml) ﾱsd 46 ﾱ 21 48 ﾱ 31 47 ﾱ 22 > 0.2
urinary excretion (ml) ﾱsd 421 ﾱ 245 570 ﾱ 356 690 ﾱ 468 < 0.05
aprotinine (mE) ﾱsd 1 ﾱ 1 2 ﾱ 1 2 ﾱ 1 < 0.05
heparine (IE) ﾱsd 37250 ﾱ 8914 38167 ﾱ 7484 37833 ﾱ 6914 > 0.2
protamine ( IE) ﾱsd 34500 ﾱ 6991 37500 ﾱ 7399 36167 ﾱ 6783 > 0.2
norepinephrine (mg) ﾱsd 1 ﾱ 1 1 ﾱ 1 2 ﾱ 1 0.1275
dobutamine (mg) ﾱsd 26 ﾱ 10 28 ﾱ 20 25 ﾱ 6 > 0.2
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Table 4. crystalloids, blood components, urinary excretion, coagulation products and catecholamine from the end of surgery till
24 hours stay on the Icu (phase 2).
variable 6% HES 130/0.42 4% gelatin 6% HES 200/0.5 p-value
(n=30) (n=30) (n=30)
saline (ml) ﾱsd 3173 ﾱ 1428 3265 ﾱ 1410 3169 ﾱ 1218 > 0.2
other crystalloides (ml) ﾱsd 1318 ﾱ 265 1289 ﾱ 326 1231 ﾱ 424 > 0.2
red cell concentrate (n)  ﾱsd 4 ﾱ 2 4 ﾱ 2 4 ﾱ 2 > 0.2
fresh frozen plasma (n) ﾱsd 4 ﾱ 1 4 ﾱ 2 4 ﾱ 1 > 0.2
platelet concentrate (n) ﾱsd 2 ﾱ 1 2 ﾱ 1 2 ﾱ 1 > 0.2
bicarbonate 8.4% (ml) ﾱsd 46 ﾱ 21 48 ﾱ 31 47 ﾱ 22 > 0.2
urinary excretion (ml) ﾱsd 2993 ﾱ 1376 3251 ﾱ 1210 3446 ﾱ 882 > 0.2
aprotinine (mE) ﾱsd 2 ﾱ 1 2 ﾱ 1 2 ﾱ 1 0.1888
heparine (IE) ﾱsd 119200 ﾱ 81597 98667 ﾱ 78300 87667 ﾱ 73693 > 0.2
protamine ( IE) ﾱsd 34500 ﾱ 6991 37500 ﾱ 7399 36167 ﾱ 6783 > 0.2
norepinephrine (mg) ﾱsd 2 ﾱ 3 9 ﾱ 9 8 ﾱ 6 < 0.05
dobutamine (mg) ﾱsd 177 ﾱ 76 276 ﾱ 150 197 ﾱ 123 0.1181
Fig. 2. Multiplateﾮ analysis: col-test.
Fig. 3. Multiplateﾮ analysis: tRaP-test.
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in the mean age of patients undergoing an open-heart
surgery resulting in higher mortality rates and an in-
creased rate of postoperative complications [13, 14].
these complications comprise a protracted Icu-stay,
the frequent application of blood products and a renal
dysfunction.
Hence a permanent verification of the colloids used
for treating hypovolemia is mandatory for an early de-
tection  of  adverse  events  and  thereby  reducing  or
even avoiding these complications in this challenging
patient population.  
the objective of these study was to compare 3 fre-
quently used colloids with regards to their safety in
clinical  use  in  cardiac  surgery.  consequently  we  fo-
cused mainly on the influence on the renal function
and the alteration of the blood coagulation as being
frequently described side effects of these preparations.
furthermore the comparison of the influence of he-
modynamics and the volume effect of the three col-
loids was a major objective of these studies. 
acute renal failure is a serious complication follow-
ing cardiac surgery and a permanent reduction in renal
function will exhibit independent effects on patient sur  -
vival that extends well beyond discharge from the hos-
pital [15, 16]. there was no difference regarding creati-
nine and urea concentration between the three groups.
furthermore we saw no difference concerning the ad-
ministration of diuretics. but our results show a signifi-
cantly lower urinary excretion in the 6% HEs 130/0.42
group during surgery (phase 1). this result surprised
since the third generation of HEs preparations (130/
0.4) is supposed to be associated with fewer changes in
kidney function than the former HEs generations. 
Even after the application of a very high dosage of
6% HEs 130/0.4 in patients undergoing neurosurgical
intervention there was no deteriorating kidney func-
tion seen [17].
boldt et al. showed in a study with cardiac patients
over the age of 80 that the use of HEs 130/0.4 was
associated with fewer changes in kidney function than
after the use of gelatin [18]. Possible reasons for the
significantly lower urinary excretion in the 6% HEs
130/0.42 group might be an influence of the addition-
al administration of crystalloids during the surgical in-
tervention and the higher Euroscore of the 6% HEs
130/0.42 group. 
our results show that the 4% gelatin group needed
significantly more norepinephrine than the two other
groups during the Icu-stay (phase 2). Hence the vol-
ume effect of gelatin can be considered as being lower
than the two HEs preparations. these results are be-
ing confirmed by boldt et al. who needed significantly
more gelatin than a “third” generation HEs prepara-
tion to obtain an equal volume effect [18]. other au-
thors saw an equal volume effect of HEs preparations
and gelatin preparations [19-22]. a limitation of our
studies is certainly the significantly higher body weight
of the gelatin group. as mentioned we administrated
each patient regardless to their body weight 500 ml of
the respective colloid as part of the anesthetic induc-
tion  resulting  in  a  lower  dosage  per  kilogram  body
weight. this may have contributed to the lower vol-
ume effect seen in the gelatin group. 
we analyzed several data for evaluating the influ-
ence  of  the  colloids  on  the  blood  coagulation  and
platelet function. aprotinin was effectively used for re-
ducing  intra-and  postoperative  blood  drainage  and
transfusion  requirements  and  thus  its  administration
can be used as a marker for evaluating the blood coag-
ulation [23]. we found a significantly higher aprotinin
administration  during  surgery  in  the  gelatin  group
compared to the other groups. the 6% HEs 200/0.5
group received significantly more aprotinin than the to
the 6% HEs 130/0.4 group. furthermore the respon-
sible surgeon considered the blood coagulation in the
HEs 200/0.5 group most frequently impaired. 
Interestingly these subjective parameters evaluating
blood  coagulation  were  confirmed  by  the  objective
measurement of platelet aggregation using multiplate
electrode analyzer. we saw a significant decrease in ag-
gregation after the administration of 6% HEs 200/0.5
in the adP-test as well as in the col-test. these tests
perform submaximal stimulation of platelet aggrega-
tion. In contrast, in the tRaP-test we saw no signifi-
cant change in aggregation. this test performs a maxi-
mal stimulation of platelet aggregation being a possible
explanation for our results. Interestingly we saw no dif-
ference  using  multiplate  electrode  analyzer  regarding
the 4% gelatin group and the 6% HEs 130/0.4 group.
our results are confirmed by several studies show-
ing an advantage of the 3rd generation of HEs prepa-
ration over the 2nd generation with regard to blood
coagulation and platelet function [9, 24-26].
there are several limitations that have to be consid-
ered  when  interpreting  our  results.  the  4%  gelatin
group was significantly taller and had a significantly
higher body weight than the 6% HEs130/0.42 group.
furthermore the Euroscore of the 6% HEs 130/0.42
group  was  significantly  higher  than  the  6%  HEs
200/0.5 group. to allow an exact comparison between
the three groups all patients should have received the
similar dosage of the colloid per kilogram bodyweight.
but this is only accomplishable in an prospective ran-
domized study and not in an obervational study. 
In summary, we have shown that gelatin has a lower
stabilizing effect on circulation during fluid resuscita-
tion. the blood coagulation was mostly impaired due
to HEs 200/0.5 confirmed by the multiplateﾮ-analysis
as well as by different clinical findings.
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